Xlife Sciences AG Reports Sustainable Growth in 2024 Valuation

On May 5, 2025, Xlife Sciences AG published their 2024 Valuation Report. The report evaluated the company's project portfolio as of December 31, 2024, with the help of CYLAD Consulting. CYLAD used the risk-adjusted net present value method, examining financial forecasts and strategic plans. The report values the portfolio between CHF 617.4 million and CHF 754.7 million, slightly up from the previous year.

The top five project companies account for 88% of the portfolio's value. The "Technology Platforms" segment holds the largest share at 50%, followed by "Biotechnology/Therapies" at 38%. Most of the portfolio's value, 76%, is from "Proof of Concept" phase projects.

CEO Oliver R. Baumann affirmed the portfolio's potential, highlighting ongoing strategic development and expansion plans. Notably, with FUSE-AI GmbH's potential U.S. listing, targeting higher valuations and broader market entry becomes a key goal.